お知らせ • May 02
BioStem Technologies, Inc. Appoints Katherine Gorrell as Chief Legal & Compliance Officer, Effective April 27, 2026 BioStem Technologies, Inc. announced the appointment of Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026. Ms. Gorrell has an extensive career advising hospital systems and health technology companies, with deep experience in health law, regulatory, transactional, compliance, governance, and risk management, as well as other business-oriented legal functions that facilitate strategic expansion and ensure operational excellence. In her role, she will oversee BioStem’s legal and compliance functions and play a central role in enterprise governance, including the integration and oversight of Medical Affairs through BioStem’s compliance framework. Most recently Ms. Gorrell served as Vice President and General Counsel at Holy Cross Health in Fort Lauderdale, Florida, where she was as a member of the Executive Team and led legal strategy across a complex healthcare enterprise. She previously served as General Counsel and Compliance Officer for AdvancedMD, a national healthcare IT company, and held in-house roles at Intermountain Healthcare and Providence Health & Services/Swedish Health Services, advising across the full spectrum of operational, regulatory, and strategic matters. Ms. Gorrell holds a JD with Honors, with a concentration in Health Law, from the University of Washington School of Law, and a Bachelor of Arts with Honors in Political Science from the University of Utah. お知らせ • Mar 23
BioStem Technologies Announces Board and Committee Changes BioStem Technologies announced the appointment of Jodi Ungrodt to its Board of Directors, where she will also serve as Chair of the Audit Committee, effective March 18, 2026. Ungrodt brings nearly three decades of financial leadership to the role, having spent her career as a senior partner at Ernst & Young advising life sciences companies on initial and secondary public offerings, business combinations, risk assessment and regulatory compliance. She is qualified to serve as a financial expert under SEC, NYSE, and NASDAQ rules. As Audit Committee Chair, Ungrodt will oversee the company’s financial reporting, internal controls and risk management practices. Her prior experience includes serving as Chair of the Audit Committee for Feeding San Diego, where she provided accounting, budgeting and risk assessment guidance for over a decade. She is also an Advisory Board Member for Life Science Cares. During her tenure at EY, Ungrodt served more than 70 companies across the Life Sciences sector. Ungrodt holds a BS in Accounting from San Diego State University and is a Certified Public Accountant and member of the American Institute of Public Accountants and the California Society of CPAs. Ungrodt replaces former board member Brandon Poe, who accepted the role of BioStem’s chief financial officer in August 2025. Poe brings more than 25 years of finance leadership experience across the healthcare and life sciences sectors. He served on BioStem’s Board of Directors for three years before joining the organization. お知らせ • Jan 22
BioStem Technologies, Inc. Announces Promotion of Barry Hassett as Chief Commercial Officer BioStem has promoted industry veteran Barry Hassett, previously the Senior Vice President of Commercial Strategy, into the role of Chief Commercial Officer to lead the newly combined commercial team. Barry has over 25 years of industry experience, including five years with BioTissue where he held the role of Vice President of Marketing, leading the initial development of its surgical and wound care business as well as its ophthalmic portfolio. お知らせ • Jan 11
BioStem Technologies, Inc. Appoints Shawn Mccarrey as Chief Commercial Officer BioStem Technologies Inc. announced it has appointed a proven life science sales leader, Mr. Shawn McCarrey, as Chief Commercial Officer. Before joining, Mr. McCarrey held the position of Chief Commercial Officer at BLUEWAVE, successfully leading the commercialization of their proprietary system in Orthotics & Prosthetics (O&P), Wound Care, and Podiatry markets. Prior to this, he served as the Vice President of Sales at Glytec, and held the role of Senior Vice President of Sales in the regenerative medicine sector at the medical device company, AxoGen. During his tenure at AxoGen, Mr. McCarrey was instrumental in boosting the company's annual growth rate from 39% to an impressive 60%. Additionally, he brings valuable leadership experience from his time at Bayer, where he significantly expanded the company's install base by 910% and grew its sales force by 250%. At Possis Medical, Mr. McCarrey was pivotal in launching 16 new products over a decade, contributing to a substantial 1,158% increase in the company's sales. お知らせ • Dec 19
Biostem Technologies Appoints Patrick Daly to Board of Directors BioStem Technologies Inc. announces it has appointed Mr. Patrick Daly to its Board of Directors. Mr. Daly is an award-winning executive leader with a strong track record of success in operations, strategy, sales, marketing, fundraising, and partnership-building. Mr. Daly is an Advisor at Pappas Capital, a private equity firm focused on the life sciences industry. Most recently, he served as Global VP Commercial Solutions and subsequently, Global VP MedTech Data Delivery, at IQVIA Holdings and was responsible for leading a global strategic MedTech Commercial Solutions business unit. Previously, he held the position of President and CEO at Cohera Medical, an early-stage commercial-stage life sciences company developing biomaterials for surgical adhesives, sealants, and drug delivery products that was acquired by global investment firm, KKR. At Cohera, Mr. Daly spearheaded the development of a novel delivery device for synthetic surgicaladhesive that maintained a two-year shelf life and received the Businesswire 2012 Medical Design Excellence Award. 